{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:25:35Z","timestamp":1778354735841,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00032\/1"],"award-info":[{"award-number":["MC_UU_00032\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000883","name":"University of Bristol","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF20SA0064340"],"award-info":[{"award-number":["NNF20SA0064340"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jacl.2025.12.024","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:20:40Z","timestamp":1767745240000},"page":"656-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["VLDL cholesterol and ASCVD risk: A population-based study"],"prefix":"10.1016","volume":"20","author":[{"given":"Mie","family":"Balling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto Gr\u00f8n","family":"Roepstorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas Alexander","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Varbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Langsted","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin B\u00f8dtker","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-8314","authenticated-orcid":false,"given":"George","family":"Davey Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00f8rge Gr\u00f8nne","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1442-4694","authenticated-orcid":false,"given":"Shoaib","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.12.024_bib1","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1093\/eurheartj\/ehac359","article-title":"Control of residual dyslipidaemic risk","volume":"43","author":"Braunwald","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.12.024_bib2","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstr\u00f6m","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.12.024_bib3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2025.12.024_bib4","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.12.024_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.12.024_bib6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/clinchem\/hvae217","article-title":"Remnant cholesterol: quantification, concentrations by sex and age, and risk of ischemic heart disease","volume":"71","author":"Balling","year":"2025","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2025.12.024_bib7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.12.024_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.12.024_bib9","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction","volume":"42","author":"Varbo","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.12.024_bib10","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins","volume":"76","author":"Balling","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.12.024_bib11","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/eurheartj\/ehx665","article-title":"U-shaped relationship of HDL and risk of infectious disease: two prospective population-based cohort studies","volume":"39","author":"Madsen","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.12.024_bib12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jacc.2022.10.019","article-title":"Elevated LDL triglycerides and atherosclerotic risk","volume":"81","author":"Balling","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.12.024_bib13","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.12.024_bib14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jacl.2025.12.024_bib15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2307\/2532098","article-title":"Estimates of absolute cause-specific risk in cohort studies","volume":"46","author":"Benichou","year":"1990","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.jacl.2025.12.024_bib16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.32614\/RJ-2017-062","article-title":"riskRegression: predicting the risk of an event using Cox regression models","volume":"9","author":"Ozenne","year":"2017","journal-title":"R J"},{"key":"10.1016\/j.jacl.2025.12.024_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120471","article-title":"Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort study","volume":"409","author":"Balling","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.12.024_bib18","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.12.024_bib19","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.12.024_bib20","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.12.024_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.12.024_bib22","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target populations for novel triglyceride-lowering therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425005604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:30:06Z","timestamp":1775215806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425005604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1933287425005604"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.12.024","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VLDL cholesterol and ASCVD risk: A population-based study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}